Dyne Therapeutics Inc, a muscular diseases therapies developer, has filed Amendment No 1 Form S-1 Registration Statement on September 10, 2020 with U.S Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $175 million by offering 10.3 million shares at the price range of $16 to $18. Assuming a successful IPO at the midpoint of the proposed range, the company expects a market capitalization of $782 million.
The company designed their proprietary FORCE platform to overcome current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Their initial focus is programs on potential pipeline expansion opportunities in additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle disease.
The Waltham, Massachusetts-based company was founded in 2017. It plans to list on the Nasdaq Global Market under the symbol “DYN.” J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriters of the IPO.
The company engages Wilmer Cutler Pickering Hale and Dorr LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
#ipo #nasdaq #deloitte #muscledisease #healthcare #therapydeveloper
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
